💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Triflupromazine

CHEMBL570 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
352.4 g/mol
LogP
5.2
Phase
4

Triflupromazine is a trifluoromethyl-substituted phenothiazine typical antipsychotic that blocks dopamine D2 receptors along with significant anti-alpha-adrenergic, antihistaminergic, and anticholinergic activity, used for the management of psychotic disorders and as an antiemetic. It is one of the lower-potency phenothiazines with marked sedative properties. Its pharmacological profile is typical of phenothiazine antipsychotics with the associated risks of extrapyramidal effects and tardive dyskinesia with long-term use.

Молекулярная масса

352,4000 g/mol

LogP

5,20

TPSA

31,80 Ų

Правило пяти Липинского

Соответствует

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CN(C)CCCN1c2ccccc2Sc2ccc(C(F)(F)F)cc21

                

                

                
                

                    
InChI

                    
InChI=1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C18H19F3N2S

                    

                    
                    

                        
HBD / HBA

                        
- / 6

                    

                    
                    

                        
Вращаемые Связи

                        
4

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
24

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
Triflupromazine is a trifluoromethyl-substituted phenothiazine typical antipsychotic that blocks dopamine D2 receptors along with significant anti-alpha-adrenergic, antihistaminergic, and anticholinergic activity, used for the management of psychotic disorders and as an antiemetic. It is one of the lower-potency phenothiazines with marked sedative properties. Its pharmacological profile is typical of phenothiazine antipsychotics with the associated risks of extrapyramidal effects and tardive dyskinesia with long-term use.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Triflupromazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL570.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5568.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.